TRIANA Biomedicines doses first patient in groundbreaking ALK+ lung cancer trial
The global, first-in-human, open-label trial will assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of TRI-611
The global, first-in-human, open-label trial will assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of TRI-611
Subscribe To Our Newsletter & Stay Updated